TY - JOUR
T1 - Interpretation of clinical studies in electrophysiology
T2 - Statistical considerations for the clinician
AU - Chieng, David
AU - Finch, Sue
AU - Sugumar, Hariharan
AU - Taylor, Andrew J.
AU - Reid, Chris
AU - Kalman, Jonathan M.
AU - Kistler, Peter M.
N1 - Publisher Copyright:
© 2020 Published on behalf of the European Society of Cardiology. All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Atrial fibrillation (AF) outcome studies play an essential role in the development of clinical evidence to improve the management of AF patients. Understanding the statistical considerations involved in study design and interpretation is crucial if electrophysiologists are to change practice. In this review, with the guidance of a medical statistician and a clinical trialist we provide an overview of important statistical issues for the clinician, with a focus on clinical studies in AF ablation. Various types of study designs including randomized controlled trials, superiority, and non-inferiority studies are described, along with their implications and limitations. Appropriate sample size calculation is fundamental to ensure statistical power and efficient resource use. Multiplicity in study endpoints is useful to encapsulate the varied effects of an intervention/treatment, although statistical adjustments are required to account for this. Finally, we discuss the limitations with the current primary endpoint used in AF ablation studies, namely, freedom from atrial tachyarrhythmia of >30 seconds, and propose AF burden as a more relevant primary endpoint, based on findings from recent clinical studies. However, technical challenges need to be overcome before AF burden can be routinely adopted, especially the need for non-invasive, long-term monitoring. The emergence of newer technologies, particularly wearable technology, offers significant promise in filling this gap.
AB - Atrial fibrillation (AF) outcome studies play an essential role in the development of clinical evidence to improve the management of AF patients. Understanding the statistical considerations involved in study design and interpretation is crucial if electrophysiologists are to change practice. In this review, with the guidance of a medical statistician and a clinical trialist we provide an overview of important statistical issues for the clinician, with a focus on clinical studies in AF ablation. Various types of study designs including randomized controlled trials, superiority, and non-inferiority studies are described, along with their implications and limitations. Appropriate sample size calculation is fundamental to ensure statistical power and efficient resource use. Multiplicity in study endpoints is useful to encapsulate the varied effects of an intervention/treatment, although statistical adjustments are required to account for this. Finally, we discuss the limitations with the current primary endpoint used in AF ablation studies, namely, freedom from atrial tachyarrhythmia of >30 seconds, and propose AF burden as a more relevant primary endpoint, based on findings from recent clinical studies. However, technical challenges need to be overcome before AF burden can be routinely adopted, especially the need for non-invasive, long-term monitoring. The emergence of newer technologies, particularly wearable technology, offers significant promise in filling this gap.
KW - Atrial fibrillation burden
KW - Intention to treat
KW - Multiple endpoint
KW - Non-inferiority
KW - Power
KW - Randomized controlled trial
KW - Sample size
KW - Statistics
KW - Superiority
KW - Survival analysis
UR - http://www.scopus.com/inward/record.url?scp=85108020604&partnerID=8YFLogxK
U2 - 10.1093/europace/euaa308
DO - 10.1093/europace/euaa308
M3 - Review Article
C2 - 33236092
AN - SCOPUS:85108020604
SN - 1099-5129
VL - 23
SP - 821
EP - 827
JO - Europace
JF - Europace
IS - 6
ER -